China Healthcare:Big is better for consistency evaluation

类别:行业研究 机构:国信证券(香港)金融控股有限公司 研究员:Jason Siu 日期:2018-01-12

Heart & brain drugs stunned 1st batch of consistency evaluation.

    On 29 Dec 2017, China’s FDA announced the first batch of 17 generic drug namesfor consistency evaluation on their quality and efficacy (仿制药质量和疗效一致性评价). Twelve of them were heart & brain medicines, among ten of which beinganti-hypertension drugs. The other five drugs were antibiotics, anti-psychotic drugs,anti-cancer and anti-viral for hepatitis and HIV. The latter anti-viral medicine fromChengdu Brilliant Pharma (成都倍特药业) was generic version of Tenofovir?(Disoproxil Fumarate) at 300mg, similar to Sinobiopharm’s (1177.HK, NR)Qingzhong.

    Sinobiopharm’s Tuotuo passed consistency evaluation.

    For HK-listed drug-maker, only one medicine was included into the list, namelySinobiopharm’s Tuotuo 托妥? (Rosuvastatin Calcium Tablets 瑞舒伐他汀钙片).

    This medicine, as a generic version of Crestor?, is well known to its cholesterollowering efficacy. Other heart and brain medicines on that list include genericversions of (1) Plavix? (Clopidogrel); (2) Monopril? (Fosinopril sodium); (3) Avapro?(Irbesartan HCl); (4) Zestril? or Prinivil? (Lisinopril); and (5) Cozaar? (Losartanpotassium). The generic version of Gefitinib Tablets (吉非替尼片) (anti-cancer)from a China A-share listed player had also been included into the list. It is worthnoting that, its tender price in 2017 stood at RMB1,680 per box (250mg) fromGuangxi Province, 29% discount to the original medicine (Iressa?) from AstraZeneca of RMB2,358 per box in Hubei and Sichuan Provinces.

    Consistency evaluation raises China drug-making standard.

    As cited by CFDA newsletter, consistent with government policy to provide qualitymedicine to Chinese masses, we see consistency evaluation will (1) improve themedicine production level from Chinese drug-makers, (2) guarantee drug safetyand effectiveness, (3) promote the sector’s technology upgrades; and (4) raisetheir global competitiveness. We expect more preferential selection of thoseChinese drug-makers whose medicines had passed the consistency evaluationduring central procurement from hospitals.

    Big is better for consistency evaluation.

    Note that, if there are more than three producers of the similar drug type (or drugstructure) getting qualified in consistency evaluation, those drug type or structurefailing to pass consistency evaluation shall not be selected in centralizedprocurement for hospitals. Moreover, we reckon that those medicines from biggerand reputed Chinese drug-makers would likely fulfill the consistency evaluationtests. Those HK-listed Chinese drug-makers with large capacities to produce qualitygeneric drugs include (1) Sinobiopharm; (2) CSPC (1093.HK, NR) and (3) FosunPharm (2196.HK, NR).

数据推荐

投资评级

更多>>
股票名称最新评级目标价研报
柳钢股份 买入 -- 研报
宝钢股份 持有 -- 研报
三钢闽光 买入 -- 研报
鞍钢股份 买入 -- 研报
新兴铸管 买入 -- 研报
紫金矿业 持有 -- 研报
宁德时代 持有 -- 研报
金风科技 买入 -- 研报
太阳能 买入 -- 研报
乐普医疗 买入 40.20 研报
中科曙光 持有 -- 研报

盈利预测

评级选股>>
股票名称11年EPS12年EPS研报
江淮汽车 0.84 0.42 研报
继峰股份 0 0 研报
小康股份 0 0 研报
星宇股份 0.72 0.78 研报
长安汽车 0.45 0.25 研报
拓普集团 0 0 研报
比亚迪 0.49 0.33 研报
均胜电子 0.42 0.52 研报
上汽集团 1.83 1.86 研报
中鼎股份 0.66 0.67 研报
银轮股份 1.01 0.29 研报

股票关注度

更多>>
股票名称关注度平均评级最新评级
上汽集团 40 持有 持有
当升科技 38 持有 买入
五粮液 37 持有 买入
金风科技 36 持有 买入
三一重工 34 持有 买入
万科A 34 买入 持有
洋河股份 34 持有 持有
华鲁恒升 33 持有 买入
烽火通信 32 持有 买入
先导智能 32 持有 买入
山西汾酒 31 持有 持有
伊利股份 31 持有 持有
中国国旅 31 持有 买入
宋城演艺 31 持有 买入
扬农化工 30 持有 持有
太阳纸业 30 持有 持有
杉杉股份 29 持有 中性

行业关注度

更多>>
行业名称关注度关注股票数买入评级数
电子信息 857 101 407
化工行业 628 59 245
生物制药 608 57 265
汽车制造 591 36 277
酿酒行业 541 17 211
建筑建材 534 46 194
机械行业 520 56 304
金融行业 472 27 209
房地产 465 34 294
酒店旅游 448 23 107
食品行业 448 30 130
商业百货 410 42 140
农林牧渔 392 30 126
交通运输 379 34 207
电子器件 373 57 188
煤炭行业 339 26 163
钢铁行业 298 26 100